BioNTech SE in the news
Innovative immunotherapies fighting diseases
Tamtam found 20 recent articles about BioNTech SE.
- BioNTech Aktienanalyse: Quartalsgewinn und 16 Milliarden Euro Liquidität – doch die Aktie nähert sich dem Jahrestief: was fehlt dem Kurs?
BioNTech stock is approaching its annual low despite third-quarter profits and significant liquidity, influenced by pipeline setbacks and a new JPMorgan rating.
- Moderna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027
The article compares Moderna and BioNTech, assessing which company has a stronger product pipeline for future growth beyond their COVID-19 vaccine revenue.
- BNTX Maintained by JP Morgan -- Price Target Raised to $93.00
JP Morgan increased BioNTech's price target to $93.00, but the stock is considered overvalued by 15.1% with significant insider selling and weak profitability.
- Trading the Move, Not the Narrative: (BNTX) Edition
A report on Biontech SE (NASDAQ: BNTX) highlights weak sentiment, a test of support, and an attractive risk-reward setup for potential trading strategies.
- BioNTech: Priority Review Voucher Purchase Hints At Much Needed Approval Shot
BioNTech's oncology prospects are improving, with several promising assets undergoing trials, while its cash reserves and COVID vaccine revenue offer stability.
- BioNTech Aktie: Das mRNA-Werk in Melbourne steht
BioNTech is facing expanded patent lawsuits from Arbutus Biopharma and Genevant in Canada and Japan, while simultaneously investing in oncology by purchasing a Priority Review Voucher, reporting strong Q3 2026 financials, and opening a new mRNA facility in Melbourne.
- BioNTech Aktie: 205 Millionen Dollar für den FDA-Turbo
BioNTech is spending $205 million to get an FDA Priority Review Voucher for its oncology pipeline and has updated its 2026 revenue forecast to 1.7-1.9 billion Euros.
- BioNTech Aktie: HC Wainwright senkt Kursziel, bleibt bei Kaufen
HC Wainwright & Co. lowered BioNTech's price target but maintained a buy rating, as BioNTech invests in oncology while reporting Q3 2026 revenues of —1,289.2 million and narrowing full-year revenue forecasts.
- BioNTech Aktie: Kanada-Klage eskaliert?
BioNTech faces an expanded patent lawsuit in Canada regarding lipid nanoparticles while also acquiring an FDA Priority Review Voucher for its oncology pipeline and reporting increased revenue.
- BioNTech Aktie: Betriebsrat knöpft sich den Vorstand vor
BioNTech faces internal challenges regarding its restructuring and employee relations, despite strong financial performance and strategic investments, raising questions about its operational execution.
- BioNTech-Aktie: Brutaler Seitwärtstrend!
BioNTech's stock dips 0.8% to 77.20 Euros after unimpressive quarterly results, as the company transitions from Covid-19 revenues to focus on oncology and mRNA technology, awaiting positive study outcomes.
- BioNTech Aktie: 205-Millionen-FDA-Wette! Gewinn-Überraschung und eine Chance bei diesem Kursbereich!
BioNTech is restructuring and focusing on oncology, with a profit in Q3 despite revenue decline, strong cash reserves, and a critical stock price.
- BioNTech Earnings Call Signals Oncology Momentum Despite Setbacks
BioNTech's Q3 earnings call revealed strong oncology pipeline progress with key drug candidates, increased revenue guidance, and substantial cash reserves despite setbacks in some clinical trials and decreased COVID-19 vaccine sales.
- BioNTech Aktie: Umsatzprognose wandert ein Stück nach oben
BioNTech raised its 2026 revenue forecast to —1.7-—1.9 billion, despite a Q3 2026 revenue decline due to lower vaccine demand, and plans to use an FDA Priority Review Voucher for its oncology pipeline.
- BioNTech Aktie: Scholar Rock verkauft Review-Voucher
BioNTech reported strong Q3 2026 financial results, updated its full-year revenue forecast, and is acquiring an FDA Priority Review Voucher for future oncology drug applications.
- BioNTech Aktie: Nettogewinn im dritten Quartal
BioNTech reported strong Q3 2026 financials, raised its full-year revenue outlook, acquired an FDA Priority Review Voucher for oncology, and adjusted R&D cost-sharing with Roche/Genentech.
- BioNTech Aktie: Der Quartalsgewinn holt das Minus nicht auf
BioNTech reported a net loss for the first nine months of 2026, despite a profitable third quarter, and updated its full-year revenue guidance.
- BioNTech Aktie: Patent-Klatsche?
BioNTech and Pfizer were found to infringe a GSK patent related to their COVID-19 vaccine, facing preliminary damages, while BioNTech also acquired an FDA Priority Review Voucher and raised its 2026 revenue forecast.
- BioNTech Aktie: Betriebsrat spürt Tauwetter beim Jobabbau
BioNTech improved internal labor relations, acquired an FDA Priority Review Voucher, and reported Q3 2026 profit despite earlier losses, leading to an increased revenue forecast.
- BioNTech Aktie: Voucher-Kauf wartet auf HSR-Freigabe
BioNTech reported Q3 2026 profits, adjusted its full-year revenue outlook, and is acquiring an FDA Priority Review Voucher for a future oncology drug submission.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like BioNTech SE?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies